Micron to exit server chips business in China after 2023 ban- Reuters
Investing.com - JPMorgan initiated coverage on Cohance Lifesciences (COHANCE:IN) with an Overweight rating and a price target of INR1,300.00.
The investment bank views Cohance, formerly known as Suven Pharma, as a technology-driven contract development and manufacturing organization (CDMO) with strong positions in high-growth niches including antibody-drug conjugates (ADCs) and oligonucleotides.
JPMorgan notes that Cohance’s integrated platform spans pharmaceutical CDMO, specialty chemicals, and advanced APIs and formulations, positioning the company to scale revenue to $1 billion by fiscal year 2030, representing a 26% compound annual growth rate (CAGR).
Despite recent headwinds affecting performance, JPMorgan believes the outlook is improving for Cohance, which is backed by experienced leadership, strategic mergers and acquisitions, and ongoing research and development and capacity investments.
The firm forecasts 20% revenue CAGR and 22% earnings CAGR for Cohance over fiscal years 2025-2028, driven by increasing contributions from niche technologies, strong CDMO momentum, and an anticipated recovery in specialty chemicals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.